 Approximately 264 subjects will be enrolled at approximately 5 study centers in the US and randomized by cohort Cohort 1 4:1; Cohorts 2 and 3 8:8:3; Cohort 4 5:1 to receive a single intramuscular dose of 1 study vaccine Cohorts 1 and 4 or a single intramuscular dose of each of 2 study vaccines Cohorts 2 and 3 administered in contralateral arms. 